<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">09285</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2022.09285</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Übersichtsartikel</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Endokrinologie / Diabetologie und Stoffwechsel </subject>
          <subject>Kinder- und Jugendmedizin</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Aktuelle Herausforderungen in der Therapie des Typ-1-Diabetes beim Kind</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Boettcher</surname>
            <given-names>Claudia</given-names>
          </name>
          <email/>
          <aff>Pediatrics</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Burckardt</surname>
            <given-names>Marie-Anne</given-names>
          </name>
          <email/>
          <aff>Pädiatrische Endokrinologie und Diabetologie, Universitätskinderspital beider Basel (UKBB), und Departement Klinische Forschung, Universität Basel</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Heldt</surname>
            <given-names>Kathrin</given-names>
          </name>
          <email/>
          <aff>Pediatrics</aff>
        </contrib>
        <contrib id="author-4" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Bachmann</surname>
            <given-names>Sara</given-names>
          </name>
          <email/>
          <aff>Pädiatrische Endokrinologie und Diabetologie (UKBB), und Departement Klinische Forschung, Universität Basel</aff>
        </contrib>
        <contrib id="author-5" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Lang-Muritano</surname>
            <given-names>Mariarosaria</given-names>
          </name>
          <email/>
          <aff>Pediatrics</aff>
        </contrib>
        <contrib id="author-6" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Hauschild</surname>
            <given-names>Michael</given-names>
          </name>
          <email/>
          <aff>Pediatrics</aff>
        </contrib>
        <contrib id="author-7" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Klee</surname>
            <given-names>Philippe</given-names>
          </name>
          <email/>
          <aff>Pediatrics, Gynecology and Obstetrics</aff>
        </contrib>
        <contrib id="author-8" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Dirlewanger</surname>
            <given-names>Mirjam</given-names>
          </name>
          <email/>
          <aff>Pediatrics, Gynecology and Obstetrics</aff>
        </contrib>
        <contrib id="author-9" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Schwitzgebel</surname>
            <given-names>Valerie M. </given-names>
          </name>
          <email>Valerie.Schwitzgebel@unige.ch</email>
          <aff>Médecin adjointe agrégée, Responsable d'Unité | Endocrinologie et diabétologie pédiatriques | 6, rue Willy Donzé | Genève 14 | 1211 | SWITZERLAND</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2022.11.23">
        <day>23</day>
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <volume>22</volume>
      <issue>47</issue>
      <fpage>767</fpage>
      <lpage>771</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Das 1921 entdeckte Insulin wurde 1922 erstmals als Therapie für Typ-1-Diabetes eingeführt. Hundert Jahre später wird es immer noch als einzige medikamentöse Behandlung eingesetzt. Die Herausforderungen, die bei der Behandlung von Typ-1-Diabetes noch zu bewältigen sind, sind nach wie vor vielfältig, wie z. B. die Ketoazidose zum Zeitpunkt der Diagnose. Obwohl Insulin lebensrettend ist, kann mit den derzeitigen Behandlungsmethoden noch keine Normalisierung des Blutzuckerspiegels erreicht werden. Die jüngsten Fortschritte haben jedoch zu einer erheblichen Optimierung der Stoffwechselkontrolle beigetragen 
L’insuline, découverte en 1921, a été introduite pour la première fois comme thérapie du diabète de type 1 en 1922. Cent ans après, elle est encore utilisée comme unique traitement médicamenteux. Les défis encore à résoudre dans la prise en charge du diabète de type 1 restent multiples, comme par exemple l’acidocétose au moment du diagnostic. Bien que l’insuline permette de sauver la vie, les traitements actuels ne permettent pas encore de normaliser la glycémie. Les avancées récentes ont néanmoins contribué à une optimisation considérable du contrôle métabolique.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
